- Imugene has attained a core patent in the largest pharmaceutical market of the world.
- The patent protects its cancer growth factor immunotherapy platform, predominantly unique combination treatments that target members of the IGF-1R and the EGFR family.
- This is the second US patent granted to Imugene in 2020; the first one being the HER-Vaxx immunotherapy patent granted in January.
- The promising results protected in the patent support the rationale for dual targeting with HER-1/2 and 3 or IGF-1R as an enhanced treatment regimen for advanced therapy customised to various types of cancer.
- Imugene is progressing considerably well to deliver on its clinical and commercial milestones, backed by decent capital position and strong executive leadership team.
Clinical stage Australian immuno-oncology firm, Imugene Limited (ASX:IMU) has recently declared that it has attained a core patent in the largest pharmaceutical market of the world.
Imugene has been granted a patent which protects its cancer growth factor immunotherapy platform, predominantly unique combination treatments that target members of the IGF-1R (insulin-like-growth factor receptor-1) and the EGFR (epidermal growth factor receptor) family.
Following the key update, IMU share price traded ~2 per cent higher at $0.054 on 6 October 2020.
This is the second US patent granted to the Company in 2020, with the first one being the HER-Vaxx immunotherapy patent granted in January. The HER-Vaxx immunotherapy patent added extra value to the Company’s most advanced cancer immunotherapy, HER-Vaxx, while protecting it in the US market until 2036.
Details of Growth Factor Immunotherapy Combination Patent
The granted patent, “HER-1, HER-3 and IGF-1R Compositions and Uses Thereof”, carries Patent Application Number: 16/292032 and Patent Number: 10,800,834. The patent protects the method of use as well as the method of composition of the Company’s Ohio State University (OSU) licensed vaccines from the laboratory of Dr Pravin Kaumaya until 2035.
Dr Kaumaya is a Professor of Medicine in the Department of Obstetrics and Gynaecology at the OSU James Comprehensive Cancer Center and Wexner Medical Center. He is an internationally known expert in the areas of vaccine research with emphasis on peptide therapy for autoimmune diseases and peptide vaccines for cancer and viral diseases. Besides, he is a member of Imugene’s Scientific Advisory Board.
Significance of Granted Patent
According to Imugene, there remains a pressing need for an effective treatment for cancers like triple-negative breast cancer (TNBC) and esophageal cancer (EC) despite the promise of targeted therapies. It is worth mentioning that TNBC is the most aggressive subtype of breast cancer and is not easy to treat.
The Company emphasized that the existing FDA-approved drugs have considerable problems of selectivity, efficacy, toxicity, safety, and development of resistance.
The promising results protected in the recent patent support the rationale for dual targeting with HER-1/2 and 3 or IGF-1R as an enhanced treatment regimen for advanced therapy customised to various types of cancer.
Imugene Riding High with Robust Leadership Team
Imugene holds a highly competent leadership team with robust oncology drug development experience, driving the Company’s vision forward.
Supported by a team of global cancer experts, Imugene is progressing strongly with its four clinical programs, linked with VAXinia, PD1-Vaxx, CHECKvacc and HER-Vaxx. To assist its continuing clinical trials, the Company recently secured $5.7 million Option Underwriting Agreement with Australia-based corporation, Bell Potter Securities Limited.
Besides, Imugene has also recently appointed Dr Rita Laeufle as a member of its executive leadership team and the Company’s new CMO (Chief Medical Officer) to support with the advancement of its important immuno-oncology programs.
In a nutshell, Imugene is progressing considerably well to deliver on its clinical and commercial milestones, backed by decent capital position and strong executive leadership team. The Company’s engineered oncolytic viruses and B-cell immunotherapies seem to place it in good stead to stay at the vanguard of the rapidly developing immuno-oncology market.